Clinical Trial Update: Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

View source ↗

Summary

An observational study sponsored by Sandoz is assessing real-world treatment retention of the adalimumab biosimilar Hyrimoz in patients with inflammatory bowel …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Hyrimoz (adalimumab)

Snippet

Sponsor: Sandoz | Conditions: Inflammatory Bowel Disease | Status: ACTIVE_NOT_RECRUITING